吉西他滨联合奥沙利铂治疗晚期胰腺癌疗效观察

目的:观察GEMOX联合方案治疗晚期胰腺癌的疗效和毒副反应。方法:19例确诊晚期胰腺癌患者接受至少2个周期的GEMOX联合方案化疗,吉西他滨1000mg/m2,静脉滴入,d1、d8;奥沙利铂130mg/m2,静脉滴入,d1。每21d重复。结果:1例CR,5例PR,8例SD,5例PD,总有效率为31.6%(6/19),毒副反应可以耐受,没有化疗相关的死亡。结论:吉西他滨加奥沙利铂联合化疗是治疗晚期胰腺癌安全有效的方案,可以使部分患者得到临床受益。但需要有Ⅲ期的随机临床试验与吉西他滨单药化疗进行比较,以明确此联合方案的优势。     

吉西他滨联合奥沙利铂治疗晚期胰腺癌疗效观察

目的：观察GEMOX联合方案治疗晚期胰腺癌的疗效和毒副反应。方法：19例确诊晚期胰腺癌患者接受至少2个周期的GEMOX联合方案化疗，吉西他滨1000mg／m^2，静脉滴入，d1、d8；奥沙利铂130mg／m^2，静脉滴入，d1。每21d重复。结果：1例CR，5例PR，8例SD，5例PD，总有效率为31．6％(6／19)，毒副反应可以耐受，没有化疗相关的死亡。结论：吉西他滨加奥沙利铂联合化疗是治疗晚期胰腺癌安全有效的方案，可以使部分患者得到临床受益。但需要有Ⅲ期的随机临床试验与吉西他滨单药化疗进行比较，以明确此联合方案的优势。     

吉西他滨联合奥沙利铂(GEMOX方案)治疗晚期恶性实体瘤的临床研究

目的:观察吉西他滨联合奥沙利铂(GEMOX方案)治疗晚期恶性实体瘤的近期疗效和不良反应.方法:30例晚期实体瘤患者,初治24例,复治6例,采用GEMOX方案:吉西他滨1000mg/m2,d1、d8静脉滴注;草酸铂130mg/m2,d1静脉滴注.21天-28天为1周期.结果:28例可评价疗效的患者中CR 0例,PR 7例,NC 14例,PD 7例,总有效率为25.0％,疾病控制率75.0％.中位生存期8.3个月, 1年生存率22.7%.主要毒副反应为骨髓抑制、恶心和呕吐.结论:吉西他滨联合奥沙利铂治疗晚期恶性实体瘤有较好的临床疗效,毒副反应轻,患者易耐受.     

吉西他滨联合奥沙利铂治疗晚期胰腺癌的临床观察

为观察吉西他滨（GEM）联合奥沙利铂（OXA）治疗晚期胰腺癌的有效性和安全性。对30例晚期胰腺癌患者,应用GEM1000mg/m2,静脉滴入30min,d1、d8;OXA100mg/m2,静脉滴入2h,d1,21d重复。至少接受2个周期的化疗。结果30例均可评价疗效,客观有效率20.00%,临床受益疗效分别为疼痛缓解率53.33%（16/30）,行为状态改善率45.33%（13/30）,体质量状态改善率36.33%（10/30）。主要不良反应为骨髓抑制、外周神经毒性及胃肠道反应,无治疗相关性死亡。初步研究结果显示,GEM联合OXA组成的GEMOX方案治疗晚期胰腺癌近期有效率较高,毒性较低,值得临床推广应用。     

吉西他滨联合奥沙利铂治疗晚期胰腺癌

目的:观察吉西他滨(GEM)联合奥沙利铂(OXA)组成的GEMOX方案治疗国人晚期胰腺癌的有效性和安全性。方法:晚期胰腺癌22例,应用GEM1000mg/m2静滴30min,d1,d8;OXA100mg/m2静滴2h,d1,d8,21天重复。至少接受2个周期的化疗,按照WHO标准进行评价。结果:22例均可评价疗效,客观有效率18·18%,临床受益疗效分别为疼痛缓解率54·55%,行为状态改善率45·45%,体重状态改善率36·33%。主要不良反应为骨髓抑制、外周神经毒性及胃肠道反应,无治疗相关性死亡。结论:吉西他滨联合奥沙利铂组成的GEMOX方案治疗国人晚期胰腺癌近期有效率较高,毒性较低,值得临床推广应用。     

吉西他滨联合奥沙利铂治疗复发性鼻咽癌的疗效

目的探讨吉西他滨联合奥沙利铂(GEMOX方案)治疗晚期鼻咽癌的临床疗效和安全性。方法选取2011年1月至2014年12月间佛山市第一人民医院采用GEMOX方案治疗晚期顺铂、氟尿嘧啶(5-Fu)耐药的鼻咽癌患者52例,吉西他滨1 000 mg/m2静滴,第1、8天;奥沙利铂65 mg/m2静滴,第1、8天,21 d为1个周期,每2个周期评价疗效1次。结果 52例患者共完成120个周期化疗,每例患者完成2~6个周期,平均3.7个周期,其中部分缓解10例(19.2%),稳定24例(46.2%),进展18例(34.6%);总有效率19.2%,疾病控制率65.4%;无进展生存期(PFS)2~24个月中位PFS为6.5个月;主要毒副反应为白细胞减少、血小板减少、恶心呕吐和肝功能损害,均以1~2度为主,患者耐受性好。结论 GEMOX方案治疗顺铂、5-Fu耐药的晚期鼻咽癌疗效好,不良反应可耐受,值得临床推广。     

吉西他滨联合奥沙利铂或顺铂治疗晚期非小细胞肺癌的随机对照研究

目的:评价吉西他滨联合奥沙利铂(GO组)与吉西他滨联合顺铂(GP组)治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应.方法:121例经病理或细胞学确诊的Ⅲ～Ⅳ期NSCLC,随机分为GO组61例,GP组60例.GO组:吉西他滨1000mg/m2,溶入0.9%NS100mL,30min静脉滴入,d1、d8;奥沙利铂135mg/m2,加入5%葡萄糖500mL中,静脉滴入2h,d2.GP组:吉西他滨1000mg/m2,溶入0.9%NS100mL,30min静脉滴入,d1、d8;DDP25mg/m2,静脉滴入,d1～d3.以上方案均每21d为1个周期,2个周期评估疗效.结果:GO组:部分缓解24例,稳定25例,总有效率为39.3%.初治有效率为45.7%,复治有效率20.0%.GP组:完全缓解1例,部分缓解21例,稳定24例,总有效率为36.7%.初治有效率为41.7%,复治有效率16.7%.两组近期疗效比较差异无统计学意义,X2=0.190,P=0.663.最常见的不良反应为骨髓抑制、消化道反应、肾功能损害及神经毒性等,其中GP组Ⅲ～Ⅳ度白细胞下降、胃肠道反应和肾毒性高于GO组;周围神经炎发生率GP组低于GO组.结论:吉西他滨联合奥沙利铂治疗晚期NSCLC的疗效与吉西他滨联合顺铂疗效相当,毒副反应轻于GP方案,可作为晚期NSCLC较理想的化疗方法之一.     

晚期胰腺癌常用一线化疗方案真实世界临床疗效观察

目的:比较白蛋白结合型紫杉醇联合吉西他滨(AG)、白蛋白结合型紫杉醇联合替吉奥(AS)、吉西他滨联合奥沙利铂(GEMOX)、吉西他滨联合替吉奥(GS)方案在真实世界一线治疗晚期胰腺癌的有效性及安全性。方法:回顾性分析2016年1月至2021年6月于我院诊治的165例晚期胰腺癌患者的病例资料,根据化疗方案不同分为四组：AG组(n=40)、AS组(n=31)、GEMOX组(n=31)、GS组(n=63),按照实体肿瘤临床疗效评价标准(RECIST)1.1版本评估临床疗效和常见不良事件评价标准(CTCAE)5.0版本评估患者的不良反应,主要研究终点为总生存期(overall survival, OS)和无进展生存期(progression-free survival, PFS),次要研究终点为客观缓解率(objective response rate, ORR)和疾病控制率(disease control rate, DCR)以及治疗相关不良反应,采用Cox风险比例模型分析影响患者预后的因素。结果:165例患者的中位OS时间为10.5个月,中位PFS时间为6.0个月,AG、AS、GEMOX、...     

吉西他滨固定剂量率输注联合奥沙利铂一线治疗晚期胰腺癌的Meta分析

背景与目的:有研究提示吉西他滨(Gemcitabine,GEM)固定剂量率(Fixed-dose rate,FDR)输注治疗晚期胰腺癌似有较好的疗效,Meta分析也显示含铂类联合化疗优于GEM单药化疗,本文试图通过Meta分析,探讨GEM FDR输注联合奥沙利铂(GEMOX)一线治疗晚期胰腺癌的地位和价值.方法:通过MEDLINE、EMBASE、ASCO等数据库及论文集检索国内外的相关文献.选择治疗组为GEMOX方案化疗,对照组为标准GEM单药化疗的晚期胰腺癌随机对照试验.由2位评价者分别按上述检索策略收集资料,按纳入标准入选,主要对总生存率及主要不良反应进行Meta分析.结果:从182篇文献中筛选出符合纳入标准的2个随机对照试验,共涉及869例患者.与GEM单药组比较,GEMOX组半年生存率提高9%(95%CI 0.03～0.16,P=0.005),1年生存率提高5%(95%CI-0.01～0.11,P=0.08),客观有效率提高6%(95%CI 0.02～0.10,P=0.006);WHO Ⅲ/Ⅳ度贫血发生率下降5%(95%CI-0.08～-0.01,P=0.01),恶心/呕吐提高13%(95%CI 0.08～0.18,P＜0.001),神经毒性增加14%(95%CI 0.04～0.24,P=0.009),粒细胞减少症、血小板减少症两组相似,差异无统计学意义.结论:现有的证据提示,GEM固定剂量率输注联合奥沙利铂组成的GEMOX方案一线治疗晚期胰腺癌可能有较好的应用前景,值得进行进一步的临床试验.     

吉西他滨单药治疗32例晚期复发转移性鼻咽癌的临床观察

为了观察吉西他滨单药治疗晚期鼻咽癌的疗效及不良反应,对32例晚期鼻咽癌患者给予单药吉西他滨治疗。吉西他滨1 000 mg/m2,持续静脉滴入30 min,d1、d8和d15,28 d为1个周期,所有患者完成>2个周期化疗。结果完全缓解2例(6.3%),部分缓解13例(40.6%),稳定9例(28.1%),有效率为46.9%(15/32),疾病控制率为75.0%(24/32)。最常见的不良反应为血液学毒性,Ⅲ～Ⅳ度贫血、白细胞和血小板减少发生率分别为9.4%(3/32)、28.2%(9/32)和15.6%(5/32)。初步研究结果提示,吉西他滨单药治疗晚期鼻咽癌有较好的疗效,毒副反应较轻,患者能耐受。     

健择联合奥沙利铂双周方案治疗胰腺癌作用探讨

目的：比较健择联合奥沙利铂双周化疗方案和健择单药每周方案治疗胰腺癌的疗效及不良反应方法：选择我科2003年11月至2005年1月胰腺癌患者30例．采用健择联合奥沙利铂双周化疗方案（设为A组：健择1000mg／m^2d1，奥沙利铂100mg／m^2d2，每隔14天进行1个周期）进行治疗；随机选择同时期使用健择单药方案（设为B组：健择1000mg／m^2单药，每周1次，连续3周，随后休息1周为1个周期）化疗的胰腺癌患者30例做对照,比较两方案治疗胰腺癌的疗效和不良反应的差异。结果：A组PR3例，SD21例，PD6例，1年生存率为16.7％（5／30）B组PR1例，SD14例，PD15例，1年生存率为10.0％（3／30）。化疗的主要不良反应包括：恶心、呕吐，骨髓抑制和外周神经毒性。结论：健择加奥沙利铂双周化疗方案在抑制肿瘤发展、延长生存期方面略优于传统健择单药方案，而两者不良反应大体相当，推荐临床使用。     

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

Gemcitabine and oxaliplatin (GEMOX) are active as first-line therapy against advanced pancreatic cancer. This study aims to evaluate the activity and tolerability of this combination in patients refractory to standard gemcitabine (GEM). A total of 33 patients (median age of 57) were included with locally advanced and metastatic evaluable diseases, who had progressed during or following GEM therapy. The GEMOX regimen consisted of 1000 mg m(-2) of GEM at a 100-min infusion on day 1, followed on day 2 by 100 mg m(-2) of oxaliplatin at a 2-h infusion; a cycle that was given every 2 weeks. All patients received at least one cycle of GEMOX (median 5; range 1-29). Response by 31 evaluable patients was as follows: PR: 7/31(22.6%), s.d. > or = 8 weeks: 11/31(35.5%), s.d. < 8 weeks: 1/31(3.2%), PD: 12/31(38.7%). Median duration of response and TTP were 4.5 and 4.2 months, respectively. Median survival was 6 months (range 0.5-21). Clinical benefit response was observed in 17/31 patients (54.8%). Grade III/IV non-neurologic toxicities occurred in 12/33 patients (36.3%), and grade I, II, and III neuropathy in 17(51%), 3(9%), and 4(12%) patients, respectively. GEMOX is a well-tolerated, active regimen that may provide a benefit to patients with advanced pancreatic cancer after progression following standard gemcitabine treatment.     

吉西他滨联合奥沙利铂治疗晚期胰腺癌30例

Objective: To evaluate the activity and safety of combination chemotherapy with gemcitabine plus oxaliplatin (GEMOX regimen) in patients of advanced pancreatic carcinoma. Methods: 30 patients with advanced pancreatic cancer were enrolled into this study. All patients received gemcitabine 1000 mg/m2, given by 30-minute intravenous infusion, on days 1 and 8 of each 21-day cycle. Oxaliplatin 100 mg/m2 was administered as a 2 h infusion on day 1 of each 21 day. Clinical outcomes for patients treated with two cycles of chemotherapy were evaluated according to WHO criteria. Results: All 30 patients were eligible for effectiveness and safety analysis. Objective response rate was approximately 20.0%. Clinical benefit response (CBR) was a composite of assessment of pain, performance status and body weight. The pain relief rate, improve-ment rate of performance status and body weight were 53.3%, 46.7% and 36.7%, respectively. The main adverse effects were bone marrow depression, peripheral nerve toxicity and gastrointestinal reaction. There was no treatment-related death during the chemotherapy. Conclusion: The high response rate with low toxicity observed in this study suggests that GEMOX regimen may be an effective alternative curative treatment for patients with advanced pancreatic carcinoma and can be used more extensively in clinical practice.     

Phase II Clinical Study on the GEMOX Regimen as Secondline Therapy for Advanced Ovarian Cancer

Aim: To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plusoxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer. Methods: 64 patients withadvanced ovarian cancer were divided into an experimental group (44 cases) and a control group (20 cases).The experimental group was treated with continuous intravenous infusion of gemcitabine at 1000 mg/m2 with afixed-dose rate of 10 mg/m2/min, on days 1 and 8 and oxaliplatin at 100 mg/m2 on day 1, IVGTT, repeated every3 weeks. The control group was treated with intravenous infusion of gemcitabine at 1000 mg/m2 within 30 minon days 1 and and oxaliplatin at 100 mg/m2 on day 1, IVGTT, again repeated every 3 weeks. CT scans or MRIwere used for review every 1-2 cycles. Results: The effective rate in the experimental group was significantly highthan control group (43.2% vs 35.0%; P < 0.05), with no obvious difference of hematologic or non-hematologictoxicity between the two groups (P > 0.05). Conclusion: GEMOX regimen is very effective to treat advancedovarian cancer, with low toxicity, good tolerance and improved life quality in patients.     

培门冬酶联合GEMOX方案治疗初治鼻腔NK/T细胞淋巴瘤临床疗效观察

  目的  观察培门冬酶联合GEMOX方案治疗初治鼻腔NK/T细胞淋巴瘤的临床疗效及安全性。   方法  分析2011年6月至2012年3月间天津医科大学肿瘤医院收治的初治鼻腔NK/T细胞淋巴瘤12例，采用P-GEMOX治疗，具体剂量为吉西他滨800~1 000 mg/m2，d1，8；奥沙利铂130 mg/m2，d1；培门冬酶2 500 IU/m2，d2，每21天为1个周期。评价疗效及不良反应。   结果  12例患者中1例出现急性胰腺炎退出治疗，余11例在接受P-GEMOX方案2个周期治疗后，完全缓解（CR）1例，部分缓解（PR）7例，疾病稳定（SD）2例，疾病进展（PD）1例，客观有效率（ORR）为72.7%，疾病控制率（DCR）为90.9%。全组患者2年总生存（OS）率达90.9%。11例患者接受中位6个周期的P-GEMOX方案化疗，不良反应发生率为81.8%，7例患者出现骨髓抑制（63.6%），5例患者出现转氨酶升高（45.5%），4例患者出现恶心呕吐（36.4%），2例患者出现凝血因子异常（18.2%），无一例患者出现严重过敏反应、血栓形成及血糖异常。   结论  培门冬酶联合GEMOX方案治疗初治鼻腔NK/T细胞淋巴瘤疗效好，但不良反应发生率较高。      

奥沙利铂联合吉西他滨治疗晚期胰腺癌的临床观察

目的:观察奥沙利铂联合吉西他滨治疗晚期胰腺癌的疗效及不良反应。方法:经影像学诊断的晚期胰腺癌18例,使用奥沙利铂85mg/m2,静脉滴注2小时,第1、8天;吉西他滨835mg/m2,静脉滴注30分钟,第1、8天,21天为1周期,至少用2周期后评价疗效。结果:18例均可评价,获得CR1例,PR3例,总有效率22·2%(4/18)。主要不良反应为骨髓抑制、外周神经毒性及恶心呕吐,无化疗相关死亡。结论:奥沙利铂联合吉西他滨治疗晚期胰腺癌患者疗效较好,不良反应可以耐受,值得深入研究。     

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

BACKGROUND: New systemic therapies are needed to improve the prognosis of patients with advanced-stage hepatocellular carcinoma (HCC). In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated. METHODS: Thirty-four patients with previously untreated advanced-stage HCC were prospectively enrolled. The GEMOX regimen consisted of gemcitabine 1000 mg/m(2) on Day 1 and oxaliplatin 100 mg/m(2) on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity. RESULTS: Thirty-two patients were assessable for efficacy and 33 for toxicity. In all, 323 treatment cycles were administered. No toxic deaths occurred. Hematological grade 3-4 toxicity consisted of thrombocytopenia (27% of patients) and neutropenia (24%), including 2 febrile neutropenia and anemia (9%). Grade 3 oxaliplatin-induced neurotoxicity was observed in 3 (9%) patients. The overall response rate was 18% (95% confidence interval [CI]: 8-34) and disease stabilization was observed in 58% of patients (including 5 minor responses), giving a disease control rate of 76%. Median progression-free and overall survival times were, respectively, 6.3 months (95% CI: 4.3-10.1 months) and 11.5 months (95% CI: 8.5-14.3 months). Treatment was significantly more effective in patients with nonalcoholic cirrhosis than in those with alcoholic cirrhosis. CONCLUSIONS: The GEMOX regimen seems to be well tolerated and active in advanced HCC, especially in patients with underlying nonalcoholic liver disease. A Phase II study of the GEMOX regimen plus cetuximab is ongoing.     

Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study

PURPOSE: To evaluate the activity and tolerance of gemcitabine in combination with oxaliplatin (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Thirty-two patients with advanced NSCLC who had disease progression after a cisplatin- and taxane-based front-line regimen were treated with gemcitabine (1500 mg/m(2) on days 1 and 8) and oxaliplatin (130 mg/m(2) on day 8) every 3 weeks. The patients' median age was 62 years and the performance status (WHO) was 0 for 11, 1 for 17 and 2 for 4 patients. The treatment was second line for 22 (69%) and >or=third line for 10 (31%) patients. RESULTS: Partial response was achieved in 5 (16%) patients, stable disease in 8 (25%) and progressive disease in 19 (59%). Two patients with stable disease and one patient with progressive disease while on previous chemotherapy experienced a partial response with GEMOX regimen. The median duration of response was 2.5 months (range, 1-11.5), the median time to tumor progression 3 months (range, 1-18) and the median survival 5.6 months (range, 1-31). Grade III neutropenia occurred in five (16%) patients, grade III thrombocytopenia in two (6%) and grade III anemia in three (9%); moreover, grades II-III asthenia was reported in eight (25%) patients and grades II-III neurotoxicity in three (9%). CONCLUSION: The GEMOX combination is a relatively active and well tolerated second-line regimen in NSCLC patients pretreated with a taxane- and/or platinum-based chemotherapy.